当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Therapeutic Reaction of Dogs to (117mSn) Colloid Intraarticular Injection

Mareiy Anad Nuyr

Objective: To determine if a reprise intraarticular( IA) injection of a drum- 117m colloid radiosynoviorthesis( RSO) agent can be safely given in the same joint 12 months after an original injection for treatment of canine elbow osteoarthritis( OA), and to estimate the pain reduction effect of the reprise injection.

Methods and Materials: Nine customer possessed tykes with grade 1 or 2 elbow OA were given an IA injection of drum- 117m colloid in both elbows, one of which had been treated ≤ 12 months before with the same RSO device. Common fluid analysis at birth (BL) and 180 days following treatment, as well as urinalysis, CBC, and serum chemistry analysis of individual samples obtained at BL and 180 days, were used to determine treatment safety. At BL and 180 days, radiographs, computed tomography, and MRI reviews were obtained to see if the evolution of the complaint varied between elbows that received one injection or two.

Findings: All post-treatment CBC, clinical chemistry, and urinalysis findings fell below normal limits. An examination of the common fluid revealed a significant (P = 0.0411) decline in the likelihood of monocytes at 180 days, consistent with the drum-117m colloid mode of action of pro-inflammatory macrophage death at the injection site. The progression of OA in elbows that received one or two injections did not differ significantly.

Conclusion: The drum-117m colloid can potentially provide a long-lasting curative response in children with elbow OA when administered as a reprise injection 12 months after the initial injection.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。